A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Epoprostenol (FLOLAN)

Prostacycline Vasodilator class · 4 generic manufacturers · 8 ANDAs filed at FDA.

First FDA approval1995-12-08
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$982,798 in CY2024 Part D spend325 claims · 41 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Epoprostenol used for?

Epoprostenol is a Prostacycline Vasodilator medication tracked in Medicare Part D.

Is there a generic for Epoprostenol?

Yes. 8 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Epoprostenol?

NADAC pricing data not currently available for this drug.

Is Epoprostenol on the FDA shortage list?

No. Epoprostenol is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Prostacycline Vasodilator3 alternatives in D1
01
Treprostinil
Brand: Orenitram
Lowest NADAC
4Generic mfrs
$1.24BCY24 Part D spend
Compare →
02
Water
Brand: Bacteriostatic Water
$0.321Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Water Solution
Brand: DILUENT
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.